LPCN
Lipocine Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.73
P/S
5.34
EV/EBITDA
-0.52
DCF Value
$0.75
FCF Yield
-92.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
-8.9%
Operating Margin
-524.7%
Net Margin
-487.1%
ROE
-59.3%
ROA
-56.6%
ROIC
-71.6%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $1.1M | $-2.4M | $-0.42 |
| FY 2025 | $2.0M | $-9.6M | $-1.69 |
| Q3 2025 | $114.6K | $-3.2M | $-0.59 |
| Q2 2025 | $622.8K | $-2.2M | $-0.41 |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$15.00
Target (Median)
$15.00
Target Range
$15.00 - $15.00
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.09
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.